Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
				short-action (4 hour) bronchodilation with fast onset (within 5 minutes) in reversible airways obstruction due to asthma. It is suitable for long term use in the relief and prevention of asthmatic symptoms. Ventolin should be used to relieve symptoms when they occur and to prevent them in those circumstances recognised by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure). Ventolin is particularly valuable as rescue medication in mild,	ţ
	•			moderate or severe asthma, provided that reliance on it does not delay the introduction	
				and use of regular inhaled cortcosteroid therapy.	
8223/0225	Discpharm Limited	Ventolin Inhaler	Salbutamol 0.1 mg	Prescription Only Medicine Salbutamol is a selective Beta-2 adrenoceptor agonist. At therapeutic doses it acts on the Beta-2 adenoceptors of bronchial muscle, with little or no action on the Beta-1 adrenoceptors of the heart. With its fast onset of action, it is particularly suitable for the management and prevention of attack in mild asthma and for the treatment of acute exacerbation in moderate and severe asthma. Salbutamol provides short-action (4 hour) bronchodilation with fast onset (within 5 minutes) in reversible airways obstruction due to asthma. It is suitable for long term use in the relief and prevention of asthmatic symptoms. Ventolin should be used to relieve symptoms when they occur and to prevent them in those circumstances recognised by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure). Ventolin is particularly valuable as rescue medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled	31st October 1994
8223/0226	Discoharm Limited	Ventolin Inhaler	Salbutamol 0.1 mg	Prescription Only Medicine Salbutamol is a selective Beta-2 adrenoceptor agonist. At therapeutic doses it acts on the Beta-2 adenoceptors of bronchial muscle, with little or no action on the Beta-1 adrenoceptors of the heart. With its fast onset of action, it is particularly suitable for the management and prevention of attack in	31st October 1994